| Hazard Information | Back Directory | [Uses]
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells[1]. | [in vivo]
Ansuvimab results in all macaques surviving after exposure to a lethal dose of Ebola virus in on day 0[1]. | [IC 50]
ZEBOV | [References]
[1] Lee A, et, al. Ansuvimab: First Approval. Drugs. 2021 Apr;81(5):595-598. DOI:10.1007/s40265-021-01483-4
[2] Corti D, et, al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016 Mar 18;351(6279):1339-42. DOI:10.1126/science.aad5224 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|